M&A Deal Summary

Azenta Acquires GENEWIZ

On September 26, 2018, Azenta acquired life science company GENEWIZ from Ampersand Capital Partners and OrbiMed Advisors for 450M USD

Acquisition Highlights
  • This is Azenta’s 5th transaction in the Life Science sector.
  • This is Azenta’s 3rd largest (disclosed) transaction.
  • This is Azenta’s 13th transaction in the United States.
  • This is Azenta’s 1st transaction in New Jersey.

M&A Deal Summary
Date 2018-09-26
Target GENEWIZ
Sector Life Science
Buyer(s) Azenta
Sellers(s) Ampersand Capital Partners
OrbiMed Advisors
Deal Type Add-on Acquisition
Deal Value 450M USD

Target

GENEWIZ

South Plainfield, New Jersey, United States
GENEWIZ, Inc. is a provider of R&D genomics services that enable research scientists within pharmaceutical, biotechnology, agriculture, environmental and clean energy, academic, and government institutions to advance their discoveries. GENEWIZ, Inc. was founded in 1999 and is based in South Plainfield, New Jersey.

Search 201,839 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Azenta

Burlington, Massachusetts, United States
Category Company
Founded 1978
Sector Life Science
Employees3,000
Revenue 656M USD (2024)
DESCRIPTION

Azenta is a provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research, and advanced cell therapies for the industry's top pharmaceutical, biotech, academic, and healthcare institutions globally. Azenta was founded in 1978 and is based in Burlington, Massachusetts.

DEAL STATS #
Overall 18 of 24
Sector (Life Science) 5 of 7
Type (Add-on Acquisition) 13 of 19
State (New Jersey) 1 of 1
Country (United States) 13 of 15
Year (2018) 3 of 3
Size (of disclosed) 3 of 17
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-08-27 Brooks Automation - Cryogenic Business

Chelmsford, Massachusetts, United States

Brooks Automation, Inc. - Cryogenic Business is a provider of advanced cryo pumps and associated products. Brooks Automation, Inc. - Cryogenic Business is based in Chelmsford, Massachusetts.

Sell $675M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-02-11 RURO

Frederick, Maryland, United States

RURO, Inc. is a software company. RURO develops state of the art computer software for research, biotechnological, pharmaceutical, healthcare and government (homeland security) laboratories in the US and worldwide. RURO, Inc. was founded in 2006 and is based in Frederick, Maryland.

Buy $15M

Seller(S) 2

SELLER

Ampersand Capital Partners

Wellesley, Massachusetts, United States

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Founded 1988
PE ASSETS 3.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.

DEAL STATS #
Overall 37 of 55
Sector (Life Science) 15 of 25
Type (Add-on Acquisition) 26 of 38
State (New Jersey) 5 of 5
Country (United States) 37 of 51
Year (2018) 4 of 6
Size (of disclosed) 3 of 13
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-09-04 Nexelis

Laval, Quebec, Canada

Nexelis is an immunology-centric CRO specialized in preclinical models and clinical assay development in single and multiplex formats and sample analysis for low-, mid- and large-scale clinical testing. the company's team of scientists and technology platforms have been instrumental in the development, qualification, and validation of assays supporting FDA filings of over 100 new molecular entities, including blockbuster biologics such as vaccines and complex large molecules.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-10-23 Genoptix

Carlsbad, California, United States

Genoptix, Inc. is one of the largest hematopathology testing laboratories in the U.S., providing thousands of oncologists and pathologists across the United States with comprehensive testing solutions in hematology and solid tumor molecular profiling. Genoptix, Inc. was founded in 1999 and is based in Carlsbad, California.

Sell $126M
SELLER

OrbiMed Advisors

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 1989
PE ASSETS 14.0B USD
Size Large
Type Sector Focused
DESCRIPTION

OrbiMed Advisors is a global healthcare centric investment firm that invests in medical device, life science, healthcare service, and medical diagnostic companies. OrbiMed maintains three investment disciplines including Public Equity, Private Equity, and Royalty Opportunities. OrbiMed's Public Equity group manages a series of public equity funds, including long/short event-driven funds and closed-end investment trusts that invests across all types of publicly-traded companies, from biopharmaceuticals to medical devices and healthcare services worldwide. OrbiMed's Private Equity group invests in start-ups through growth equity financings. OrbiMed prefers to be the lead investor and will consider opportunities across North America, Asia, Europe and Israel. OrbiMed's Royalty practice provides commercial-stage healthcare companies with non-dilutive structured debt capital. OrbiMed was formed in 1989 and is based in New York City.

DEAL STATS #
Overall 3 of 4
Sector (Life Science) 2 of 3
Type (Add-on Acquisition) 1 of 1
State (New Jersey) 1 of 1
Country (United States) 2 of 3
Year (2018) 3 of 3
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-06-02 Tricida

South San Francisco, California, United States

Tricida is a pharmaceutical company focused on developing and commercializing its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Tricida was founded in 2013 and is based in South San Francisco, California.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-01-30 Arcutis

Westlake Village, California, United States

Arcutis is focused on developing topical medicines for the treatment of skin diseases. The company’s lead program, ARQ-151, is a topical formulation of roflumilast that is currently in Phase 2 studies for the treatment of plaque psoriasis and atopic dermatitis. The company’s second program, ARQ-250, is a topical JAK1-inhibitor in preclinical development for the treatment of various autoimmune diseases affecting the skin. Arcutis was founded in 2016 and is based in Westlake Village, California.

Sell -
Mergr

Product

Company

Legal